Key result
Low-dose aspirin is recommended to prevent stroke and death in ischemic cerebrovascular disease pending ongoing trials.
Why the study?
Does low-dose aspirin compared to high-dose aspirin provide optimal prevention of stroke and death in patients with ischemic cerebrovascular disease?
Does low-dose aspirin compared to high-dose aspirin provide optimal prevention of stroke and death in patients with ischemic cerebrovascular disease?
The review recommends using low-dose aspirin (75 mg daily) for stroke prevention in ischemic cerebrovascular disease due to lack of definitive evidence for higher doses.
Answers are grounded in this paper and cite their sources.
Supports interim low-dose aspirin use in ischemic cerebrovascular disease; leaves open optimal dosing versus higher regimens pending trials.
BACKGROUND: A vast consensus exists in defining a narrow range of recommended daily doses of aspirin, ie, 75 to 160 mg, for the prevention of myocardial infarction, stroke, and vascular death in patients with different manifestations of coronary hearth disease. In contrast, for patients with cerebrovascular disease, a much larger degree of uncertainty still exists, with recommendations ranging from 30 to 1300 mg daily. SUMMARY OF COMMENT: The contention that higher doses of aspirin (650 to 1300 mg) are more effective than lower doses in stroke prevention is based on indirect and selective comparisons of different trial data, mini-meta-analyses, or subgroup analyses of individual trials. In the absence of definitive evidence from direct randomized comparisons of low-dose versus high-dose aspirin in trials of adequate size to detect a moderate difference between the two, the biological hypotheses that underpin the suggestion of greater efficacy of higher aspirin doses in cerebrovascular disease patients are reviewed and disputed. Practical implications of the use of higher doses of aspirin are also assessed on the basis of theoretical calculations of absolute benefits and risks. CONCLUSIONS: Until additional information from ongoing trials is available, good clinical practice should dictate the use of the lowest dose of aspirin shown effective in the prevention of stroke and death in patients with ischemic cerebrovascular disease, ie, 75 mg daily.
No takes yet. Share an insight, caveat, or question.
Gerald J. Roth (1996) conducted a review in Ischemic Cerebrovascular Disease. Aspirin vs. Higher doses (650 to 1300 mg) was evaluated on Prevention of stroke and death. Aspirin at a low dose of daily is recommended for the prevention of stroke and death in patients with ischemic cerebrovascular disease, pending definitive evidence from ongoing trials.
Synapse has enriched 10 related papers. Consider them for comparative context: